| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | MURF | Common Stock, par value $0.0001 per share ("Shares") | 2,003,324 | 22 Sep 2023 | See footnotes | F1, F2 | |||||
| holding | MURF | Shares | 516,987 | 22 Sep 2023 | See footnotes | F3, F4 |
| Id | Content |
|---|---|
| F1 | Reflects 2,003,324 Shares received by Ms. Lewis-Hall as consideration pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 8, 2022 and as amended on January 27, 2023 and May 11, 2023, by and among the Company, Conduit Pharmaceuticals Limited, a Cayman Islands exempted company ("Conduit"), and Conduit Merger Sub, Inc., a Cayman Islands exempted company and a wholly-owned subsidiary of MURF (the "Merger Sub"). As a result of, and upon consummation of the transactions contemplated by, the Merger Agreement, the Company changed its name from "Murphy Canyon Acquisition Corp." to "Conduit Pharmaceuticals Inc." |
| F2 | The Shares are held of record by Intelmed LLC ("Intelmed"). Ms. Lewis-Hall is the Managing Director of Intelmed and in such capacity has voting and investment discretion with respect to the Shares held of record by Intelmed. By virtue of this relationship, Ms. Lewis-Hall may be deemed to share beneficial ownership of the Shares held of record by Intelmed. Ms. Lewis-Hall disclaims any such beneficial ownership except to the extent of her pecuniary interest therein. |
| F3 | Reflects 516,987 Shares received by Mr. Emerson Hall, Jr. as consideration pursuant to the Merger Agreement. |
| F4 | Such Shares are held by Ms. Lewis-Hall's spouse, Mr. Emerson Hall, Jr. As Mr. Hall's spouse and by virtue of their relationship, Ms. Lewis-Hall may be deemed to share beneficial ownership of such shares held by record by Mr. Emerson Hall, Jr. Ms. Lewis-Hall disclaims any such beneficial ownership except to the extent of her pecuniary interest therein. |